This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Felner, E. I.
Right arrow Articles by White, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Felner, E. I.
Right arrow Articles by White, P. C.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 105 No. 4 April 2000, p. e55

ELECTRONIC ARTICLE:
Prepubertal Gynecomastia: Indirect Exposure to Estrogen Cream

Received Aug 9, 1999; accepted Dec 1, 1999.

Eric I. Felner and Perrin C. White

From the Department of Pediatrics, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas

Objective.  To describe the clinical course of 3 prepubertal boys who presented with gynecomastia resulting from indirect exposure to a custom-compounded preparation of estrogen cream used by each child's mother.

Methodology.  Each child was initially referred to the Children's Medical Center of Dallas' Endocrinology Center and followed for over 1 year.

Results.  All 3 boys presented with gynecomastia and elevated estradiol levels. Two had accelerated growth and advanced bone ages. Within 4 months after each child's mother discontinued use of the topical estrogen preparation, each child's gynecomastia regressed and estradiol levels returned to normal.

Conclusion.  Indirect exposure to excessive amounts of topical estrogen may cause gynecomastia, rapid changes in growth, and advanced bone age in prepubertal children. Because custom-compounded topical estrogen preparations are not regulated by the Food and Drug Administration and may contain high concentrations of estrogen, we recommend that women requiring estrogen use an alternate form of estrogen delivery if they are in frequent close contact with children.  Key words:  estradiol, custom-compounded.




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
T. D. Nebesio, M. M. Davis, D. F. Billmire, and E. A. Eugster
Giant Cell Fibroblastoma Masquerading as Prepubertal Gynecomastia
Clinical Pediatrics, May 1, 2005; 44(4): 355 - 357.
[PDF]